skingenix
Application on Cutaneous Wounds

 
Steps
 
Illustrations
1. Wash hands thoroughly before applying MEBO.
 

2. Gently remove any debris from the wound with sterilized cotton swab.
3. Clean the skin around the wound with alcohol swab. (Caution: don¡¯t touch the wound with alcohol.)
4. Squeeze the prescribed amount* of MEBO onto the ruler side of the inner dressing package. Use a sterile tongue depressor to transfer the MEBO onto the wound.  Apply 2mm ¨C 3mm layer of the MEBO evenly over the ulcer, twice daily.
 
 
 
 
 
 
5. Cover the ulcer with sterile gauze pad. Wrap a soft, dry gauze bandage over the pad if needed. Secure the wrap gauze bandage with adhesive tape. (Make sure the adhesive is secured to the gauze and not to the skin).

6. After 12 hours, remove the dressing; gently remove any excess MEBO or debris with sterile cotton swab, repeat the above procedures.
 

 * The amount of MEBO to be applied will vary depending upon the size of the ulcer area.

 

 Use the following table to determine the appropriate amount of MEBO
to be applied to ulcer surface area per square centimeters

 Ulcer Surface Area (cm2)

 0.5

1

 2

 3

 4

 5

 6

 7

 8

 9

10 

 Amount of MEBO: Length (cm) of squeezed out Ointment

0.3

 0.6

 1.2

 1.8

 2.4

 3.0

 3.6

4.2 

 4.8

 5.6

 6.0

 
Copyright © 2009-2010 SKINGENIXWEB.COM. All Rights Reserved
The Skingenix, Inc. website has been designed for the audience worldwide. This website contains information about products which may or may not be available in different countries. In addition, the official approval or market clearance for indications of use may also differ per each country. Please consult individual country sites for approved uses and any applicable restrictions.The research data disclosed in this website is wholly for the purpose of scientific information exchange and is not intended for marketing or promotional uses.

Please note that Skingenix's drug product MEBO® Wound Ointment has not been approved by the Food and Drug Administration for any indication of use in the United States. It is currently under the status of Investigational New Drug (Phase II) for patients with burn injuries, venous stasis ulcers and diabetic foot ulcers.